上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (11): 1411-.doi: 10.3969/j.issn.1674-8115.2012.11.004

• 专题报道（病原微生物学） • 上一篇    下一篇

重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性评估

陈 旭1, 王文奎2, 孟志民3, 王 雅3, 邵妍妍3, 韦 栋3, 樊宁远3, 倪语星1, 韩立中1   

  1. 上海交通大学 医学院附属瑞金医院 1.临床微生物科, 2.烧伤科, 3.临床医学院检验系, 上海 200025
  • 出版日期:2012-11-28 发布日期:2012-11-30
  • 通讯作者: 韩立中, 电子信箱: lizhong_han@yahoo.com。
  • 作者简介:陈 旭（1988—）, 男, 硕士生；电子信箱: chenxu917@hotmail.com。
  • 基金资助:

    上海市自然科学基金（09ZR1419200）；卫生公益性行业科研专项基金 (201002021)

Evaluation of in vitro bactericidal activity of recombinant lysostaphin against Staphylococcus aureus isolated from burn wounds

CHEN Xu1, WANG Wen-kui2, MENG Zhi-min3, WANG Ya3, SHAO Yan-yan3, WEI Dong3, FAN Ning-yuan3, NI Yu-xing1, HAN Li-zhong1   

  1. 1.Department of Clinical Microbiology, 2.Department of Burns, 3.Faculty of Medical Laboratory Science, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2012-11-28 Published:2012-11-30
  • Supported by:

    Natural Science Foundation of Shanghai, 09ZR1419200；Special Fund for Health-scientific Research in the Public Interest, 201002021

PDF (PC)

1110

摘要：

目的 评估重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性。方法 收集烧伤创面分离的金黄色葡萄球菌共171株。采用琼脂稀释法测定临床烧伤常用药物万古霉素、红霉素、克林霉素、头孢西丁及磺胺甲噁唑对金黄色葡萄球菌的最低抑菌浓度（MIC）；根据头孢西丁的MIC值区分耐甲氧西林的金黄色葡萄球菌（MRSA）和甲氧西林敏感的金黄色葡萄球菌（MSSA）；根据万古霉素、红霉素、克林霉素、磺胺甲噁唑的药物敏感试验结果对金黄色葡萄球菌进行耐药性分析。采用微量肉汤稀释法检测重组溶葡萄球菌素对金黄色葡萄球菌的MIC，计算50%最低抑菌浓度(MIC50)和90%最低抑菌浓度（MIC90)。结果 根据药物敏感试验结果，收集的171株金黄色葡萄球菌对磺胺甲噁唑、红霉素、克林霉素和万古霉素的耐药率分别为99.4%、88.3%、87.1%和0，其中MRSA有146株（占85.4%）。重组溶葡萄球菌素对金黄色葡萄球菌的MIC范围为0.015~ 0.5 U/mL，MIC50为<0.015 U/mL，MIC90为0.03 U/mL。结论 重组溶葡萄球菌素对金黄色葡萄球菌具有较好的体外抗菌活性。在金黄色葡萄球菌耐药性日益增强的情况下，对于临床烧伤创面感染的预防和治疗，重组溶葡萄球菌素是一种极具开发潜力的新药。

关键词: 重组溶葡萄球菌素, 金黄色葡萄球菌, 体外抗菌活性, 最低抑菌浓度, 烧伤

Abstract:

Objective To evaluate the in vitro bactericidal activity of recombinant lysostaphin against Staphylococcus aureus isolated from burn wounds. Methods One hundred and seventy-one Staphylococcus aureus strains were isolated from burn wounds. The minimum inhibitory concentrations (MIC) of vancomycin, erythromycin, clindamycin, cefoxitin and sulfamethoxazole, which were common drugs used for burns in clinics against Staphylococcus aureus were measured by agar dilution method. Methicillin-resistant Staphylococcus aureus (MRSA) and methicillinsensitive Staphylococcus aureus (MSSA) were divided according to the MIC of cefoxitin. Drug resistance analysis of Staphylococcus aureus was conducted according to the results of antimicrobial susceptibility tests of vancomycin, erythromycin, clindamycin and sulfamethoxazole. The MIC of recombinant lysostaphin against Staphylococcus aureus was measured by micro-broth dilution method, and 50% minimun inhibitory concentration (MIC50) and 90% minimun inhibitory concentration (MIC90) were calculated. Results According to the results of antimicrobial susceptibility tests, the resistance rates of Staphylococcus aureus to sulfamethoxazole, erythromycin, clindamycin and vancomycin were 99.4%, 88.3%, 87.1% and 0 respectively, and the prevalence of MRSA was 85.4%(146 strains). The MIC of recombinant lysostaphin against Staphylococcus aureus ranged from 0.015 to 0.5 U/mL, with MIC50 of <0.015 U/mL and MIC90 of 0.03 U/mL. Conclusion Recombinant lysostaphin has favorable in vitro bactericidal activity against Staphylococcus aureus. With the increasing resistance of Staphylococcus aureus to clinical drugs, recombinant lysostaphin may potentially be a potent drug for Staphylococcus aureus infection of the burn wounds.

Key words: recombinant lysostaphin, Staphylococcus aureus, in vitro antibacterial activity, minimal inhibitory concentration, burn wound